Erin Wright
Stock Analyst at Morgan Stanley
(1.28)
# 3,531
Out of 4,898 analysts
225
Total ratings
60%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MOH Molina Healthcare | Downgrades: Equal-Weight | $364 → $266 | $221.55 | +20.06% | 2 | Jul 10, 2025 | |
| PAHC Phibro Animal Health | Maintains: Equal-Weight | $21 → $26 | $30.66 | -15.20% | 23 | Jun 25, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $166 → $181 | $160.97 | +12.44% | 11 | Jun 13, 2025 | |
| MCK McKesson | Maintains: Overweight | $745 → $770 | $709.59 | +8.51% | 7 | Jun 11, 2025 | |
| BTSG BrightSpring Health Services | Maintains: Overweight | $20 → $25 | $20.31 | +23.09% | 3 | May 9, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $548 → $558 | $533.37 | +4.62% | 15 | May 5, 2025 | |
| CI The Cigna Group | Maintains: Overweight | $379 → $390 | $303.27 | +28.60% | 5 | May 5, 2025 | |
| PETS PetMed Express | Maintains: Underweight | $3.5 → $3.2 | $3.32 | -3.61% | 12 | Apr 17, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $272 → $249 | $202.28 | +23.10% | 22 | Apr 15, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $20 → $19 | $20.20 | -5.94% | 8 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 → $13 | $14.90 | -12.75% | 11 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $243 → $238 | $154.96 | +53.59% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $301 → $285 | $230.67 | +23.55% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $16.21 | +41.89% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $168.09 | +2.33% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $643 → $551 | $340.67 | +61.74% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $9 → $7 | $11.52 | -39.24% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $73.44 | -11.49% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $64.78 | +54.37% | 4 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $304.10 | +93.03% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $249.62 | +20.18% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $13.58 | +209.28% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $204.85 | +40.59% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $159.40 | +120.83% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $2.74 | +1,505.84% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $323.50 | -44.05% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $81.31 | -79.09% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $37.99 | +218.50% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $434.86 | +33.38% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $11.09 | +215.74% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $150.52 | +36.19% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $19.27 | -42.92% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $162.80 | -3.56% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $21.08 | +80.27% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $8.12 | +109.36% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $467.51 | -34.12% | 1 | Oct 25, 2017 |
Molina Healthcare
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $364 → $266
Current: $221.55
Upside: +20.06%
Phibro Animal Health
Jun 25, 2025
Maintains: Equal-Weight
Price Target: $21 → $26
Current: $30.66
Upside: -15.20%
Cardinal Health
Jun 13, 2025
Maintains: Overweight
Price Target: $166 → $181
Current: $160.97
Upside: +12.44%
McKesson
Jun 11, 2025
Maintains: Overweight
Price Target: $745 → $770
Current: $709.59
Upside: +8.51%
BrightSpring Health Services
May 9, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $20.31
Upside: +23.09%
IDEXX Laboratories
May 5, 2025
Maintains: Overweight
Price Target: $548 → $558
Current: $533.37
Upside: +4.62%
The Cigna Group
May 5, 2025
Maintains: Overweight
Price Target: $379 → $390
Current: $303.27
Upside: +28.60%
PetMed Express
Apr 17, 2025
Maintains: Underweight
Price Target: $3.5 → $3.2
Current: $3.32
Upside: -3.61%
Align Technology
Apr 15, 2025
Maintains: Overweight
Price Target: $272 → $249
Current: $202.28
Upside: +23.10%
Envista Holdings
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $20 → $19
Current: $20.20
Upside: -5.94%
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $14.90
Upside: -12.75%
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $154.96
Upside: +53.59%
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $301 → $285
Current: $230.67
Upside: +23.55%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $16.21
Upside: +41.89%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $168.09
Upside: +2.33%
Oct 23, 2024
Maintains: Overweight
Price Target: $643 → $551
Current: $340.67
Upside: +61.74%
Oct 11, 2024
Maintains: Underweight
Price Target: $9 → $7
Current: $11.52
Upside: -39.24%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $73.44
Upside: -11.49%
Nov 2, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $64.78
Upside: +54.37%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $304.10
Upside: +93.03%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $249.62
Upside: +20.18%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $13.58
Upside: +209.28%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $204.85
Upside: +40.59%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $159.40
Upside: +120.83%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $2.74
Upside: +1,505.84%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $323.50
Upside: -44.05%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $81.31
Upside: -79.09%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $37.99
Upside: +218.50%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $434.86
Upside: +33.38%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $11.09
Upside: +215.74%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $150.52
Upside: +36.19%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $19.27
Upside: -42.92%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $162.80
Upside: -3.56%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $21.08
Upside: +80.27%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $8.12
Upside: +109.36%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $467.51
Upside: -34.12%